BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22378594)

  • 1. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
    Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
    Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
    [No Abstract]   [Full Text] [Related]  

  • 2. Target-selective photo-degradation of HIV-1 protease by a fullerene-sugar hybrid.
    Tanimoto S; Sakai S; Matsumura S; Takahashi D; Toshima K
    Chem Commun (Camb); 2008 Nov; (44):5767-9. PubMed ID: 19009075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
    Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
    Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling interactions between C₆₀ antiviral compounds and HIV protease.
    Al Garalleh H; Thamwattana N; Cox BJ; Hill JM
    Bull Math Biol; 2015 Jan; 77(1):184-201. PubMed ID: 25583353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
    Katzenstein D; Ogden R
    Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
    [No Abstract]   [Full Text] [Related]  

  • 9. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
    Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
    Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies.
    Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE
    Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742
    [No Abstract]   [Full Text] [Related]  

  • 13. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
    Stoddart CA; Liegler TJ; Mammano F; Linquist-Stepps VD; Hayden MS; Deeks SG; Grant RM; Clavel F; McCune JM
    Nat Med; 2001 Jun; 7(6):712-8. PubMed ID: 11385509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
    Halder AK; Jha T
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor.
    Schimer J; Pávová M; Anders M; Pachl P; Šácha P; Cígler P; Weber J; Majer P; Řezáčová P; Kräusslich HG; Müller B; Konvalinka J
    Nat Commun; 2015 Mar; 6():6461. PubMed ID: 25751579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
    Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
    J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.